Pozen, GSK get another approvable letter for migraine drug

The FDA again delayed approval of the migraine drug Trexima, seen by Pozen and GlaxoSmithKline as a successor to GSK's Imitrex. Pozen's CEO said a small, short-term clinical study may be needed to address toxicity issues raised by the FDA, which would delay the drug's launch by several months.

View Full Article in:

Forbes · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC